Artane 0.4%

Quick links to important sections

Artane 0.4%

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Artane 0.4%

What is Artane 0.4%?

Artane 0.4% is a pharmaceutical formulation containing trihexyphenidyl hydrochloride in an oral solution form. It belongs to a class of medications known as antispasmodics or anticholinergics. This specific concentration provides a liquid alternative for patients who require precise titration or have difficulty swallowing solid oral dosage forms.

Therapeutic Purpose

The primary function of Artane 0.4% is to address symptoms associated with various forms of parkinsonism. It works by targeting imbalances in the central nervous system, specifically by inhibiting the action of acetylcholine, a neurotransmitter that influences muscle movement. By correcting this chemical imbalance, the medication helps stabilize motor function.

Clinical Applications

Artane 0.4% is commonly utilized in the following clinical contexts:

  • Parkinson’s Disease: It serves as an adjunctive treatment to manage motor-related symptoms such as tremors, muscle rigidity, and involuntary movements.
  • Drug-Induced Extrapyramidal Disorders: It is used to control side effects—such as restlessness or abnormal muscle contractions—that can occur during treatment with certain antipsychotic or neuroleptic medications.
  • Postencephalitic and Arteriosclerotic Parkinsonism: It is applied to alleviate neurological symptoms resulting from brain inflammation or vascular changes.

Mechanism of Action

As an anticholinergic agent, trihexyphenidyl exerts a direct inhibitory effect on the parasympathetic nervous system. It also exhibits a relaxing effect on smooth muscle tissue. In the brain, it helps restore the balance between dopamine and acetylcholine, which is essential for maintaining smooth, coordinated physical movements.

Regulatory References

  1. Trihexyphenidyl Hydrochloride Oral Solution USP label

What side effects are possible with Artane 0.4%?

Possible side effects and safety information

Trihexyphenidyl hydrochloride (Artane 0.4%), an anticholinergic agent, has an officially documented safety profile detailing adverse reactions across multiple physiological systems. The occurrence of side effects is frequently related to the drug's activity on the parasympathetic nervous system, as outlined in government regulatory labeling.

Officially Documented Side Effects and Frequency

Minor side effects are reported in the official label to occur in 30 to 50 percent of all patients, reflecting a common classification. These effects often become less pronounced, and may even disappear, as treatment continues. Commonly observed reactions include dryness of the mouth, blurred vision, dizziness, mild nausea, and nervousness.

Adverse reactions are classified by affected system-organ classes:

  • Nervous System and Psychiatric: Includes drowsiness, headache, weakness, mental confusion, and agitation. Psychiatric events, such as delusions and hallucinations, have been reported. The onset of toxic psychosis can occur quickly, generally within days of initiating therapy.
  • Ocular: Effects can lead to dilation of the pupil and increased intraocular tension. The development of angle-closure glaucoma has been associated with long-term treatment.
  • Gastrointestinal and Genitourinary: Common effects are constipation and vomiting. Effects on the urinary system include urinary hesitancy and urinary retention.

Serious Safety Considerations and Special Populations

Serious adverse reactions documented in prescribing information include Neuroleptic Malignant Syndrome (NMS), which has been reported following dose reduction or abrupt discontinuation. Other severe reactions include paralytic ileus and fatal hyperthermia resulting from severely impaired sweating (anhidrosis).

Geriatric patients (over 60) frequently show increased sensitivity to anticholinergic drugs and may be at higher risk for mental confusion and delirium. Patients with arteriosclerosis and the pediatric population also have specific safety considerations documented in the official labels. Use requires caution in individuals with obstructive diseases of the gastrointestinal or genitourinary tracts.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Artane (Trihexyphenidyl) overdose is defined by severe manifestations of anticholinergic toxicity.

Overdose Scope

Domain Official Regulatory Statements
Documented Overdose Presentations Symptoms include those of Central Anticholinergic Syndrome: agitation, mental confusion, delirium, hallucinations, and psychotic reactions. Peripheral signs are mydriasis, tachycardia, flushing, and severe dryness of the mouth and skin.
Physiological Systems Affected Central Nervous System, Circulatory system, Respiratory system, and Gastrointestinal system (risk of paralytic ileus).
Population-specific Overdose Notes Overdose has been associated with a risk of death, which is noted to occur especially in children. Patients with arteriosclerosis may exhibit heightened reactions of mental confusion and disturbed behavior.
Emergency-response statements Seek immediate medical attention following any suspected overdose. Call emergency services if the person has collapsed, is having a seizure, has trouble breathing, or cannot be awakened.

Overdose Classifications (High-level)

Classification Official Regulatory Statement
Severity classification Overdose may be associated with life-threatening outcomes, including circulatory failure, respiratory failure, and progression to coma.
Supportive Management Treatment is designated as symptomatic and supportive. Procedures include maintaining an adequate airway and using Diazepam to manage excitement and convulsions.

Official Overdose Statements

  • Documented severe manifestations include convulsions, extreme hyperpyrexia, and potential for respiratory or circulatory failure.
  • The regulatory guidance mandates that suspected overdose requires immediate medical attention.

Connection to the overall overdose profile: Regulatory documents explicitly define the overdose state by detailing the spectrum of central and peripheral anticholinergic signs that can lead to life-threatening systemic outcomes. This profile establishes the critical need to seek urgent emergency services when these specific, severe symptoms are observed.

Therapeutic Uses of Artane 0.4%

The liquid formulation of Artane (Trihexyphenidyl) is considered relevant in situations involving certain distressing symptoms of specific movement disorders, where additional symptomatic support is needed. The medication is applied across therapeutic domains involving parkinsonism, including idiopathic, postencephalitic, and arteriosclerotic forms. It is also relevant for managing extrapyramidal disorders associated with certain central nervous system drugs, such as phenothiazines.

Supportive Management for Symptoms

This medicine is commonly used across conditions characterized by periods of heightened symptoms of rigidity and tremor. It is relevant for managing symptoms that interfere with daily comfort, such as muscle stiffness, involuntary shaking, and acute dystonic reactions. This application may assist with coping more steadily with symptom fluctuations, by easing symptoms related to increased neurological or muscular activity. It is also commonly used to help with the non-motor symptom of sialorrhea (excessive drooling).

It is considered relevant because it contributes to improved comfort during periods of heightened symptoms, helping patients cope more steadily with symptom fluctuations. This support is often provided alongside primary antiparkinsonian agents when symptoms persist.


Quick Fact: Supportive Management for Symptoms

The medication is relevant in clinical settings that involve acute or unstable symptom patterns, such as sudden muscle spasms, and contributes to easing discomfort associated with chronic conditions like Parkinson's disease, including tremor and rigidity.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Artane 0.4%?

Population eligibility for Artane (trihexyphenidyl) is strictly defined by regulatory documents, listing absolute prohibitions and populations requiring caution. The medicine is primarily allowed for adults diagnosed with Parkinson's disease or drug-induced extrapyramidal disorders.

Use is strictly contraindicated (prohibited) in patients with:

  • Known hypersensitivity to trihexyphenidyl or any of the formulation's ingredients.
  • Narrow-angle glaucoma, as long-term use has been associated with a risk of blindness.
  • Obstructive diseases of the gastrointestinal tract (e.g., stenosing peptic ulcer, paralytic ileus).
  • Obstructive diseases of the genitourinary tract (e.g., prostatic hypertrophy with urinary retention).

Restrictions and Conditions for Use:

  • Pediatric Patients: Safety and effectiveness have not been established in children, and use is generally not recommended.
  • Older Adults (Geriatric): Use requires caution due to increased sensitivity to anticholinergic effects; low initial doses and close monitoring are necessary.
  • Organ Function: Caution is advised for patients with renal impairment or hepatic impairment.
  • Pregnancy and Lactation: Use is not recommended during pregnancy (Category C) unless the potential benefit justifies the risk, and it is also not recommended while breastfeeding.

What should I know about interactions with other medicines?

Artane 0.4%, which contains the active ingredient Trihexyphenidyl, has an official regulatory profile defined by specific pharmacodynamic and exposure-related constraints. The most stringent restriction is that this medicine is formally contraindicated in patients with established narrow-angle glaucoma due to the potential for angle closure, which is linked to its parasympatholytic activity.

Documented Pharmacodynamic Effects

Co-administration with other medicines possessing anticholinergic activity (such as tricyclic antidepressants or phenothiazines) results in additive anticholinergic effects, as noted in prescribing information. Similarly, the co-administration of Trihexyphenidyl with CNS depressants, including alcohol, cannabinoids, barbiturates, or opiates, is documented to produce additive sedative effects. Specific antagonism has been noted in regulatory documents regarding the gastrointestinal effects of certain agents like metoclopramide or domperidone.

Exposure and Population Constraints

Official labeling addresses the co-use of Trihexyphenidyl with levodopa, noting that the absorption of levodopa may be reduced, and the use of the combination may necessitate a dose reduction for each agent. Furthermore, a population-specific note highlights that geriatric patients (those over 60) may exhibit increased sensitivity, which can heighten the potential risk associated with these additive anticholinergic interactions.

Mechanism of Action

Artane (Trihexyphenidyl) Mechanism of Action

Antagonism of Muscarinic Receptors

Artane (trihexyphenidyl) exerts its effect within the central nervous system (CNS) by functioning as a selective muscarinic acetylcholine receptor antagonist. This core mechanism involves a direct molecular interaction in which trihexyphenidyl binds competitively to postsynaptic muscarinic receptors, particularly the M1 subtype, blocking their activation by the endogenous neurotransmitter acetylcholine. This binding modifies early molecular steps in the cholinergic pathway, leading to a substantial decrease in the excitability of cholinergic neurons. The inhibition of these receptors reduces the overall activity of acetylcholine-mediated signaling within the affected neural circuits.

System-Level Cholinergic Modulation

Within the basal ganglia, the activity of the motor system is mediated by a functional balance between inhibitory dopaminergic pathways and excitatory cholinergic pathways. Trihexyphenidyl's anticholinergic activity decreases the functional dominance of the excitatory cholinergic pathway. This specific pathway adjustment within the motor control circuits influences the physiological signaling of motor command signals, resulting in altered output activity in the extrapyramidal system.

Dosage and Administration Information

Official Administration Guidelines

Trihexyphenidyl hydrochloride (Artane 0.4%) is officially administered via the oral route, supplied as an oral solution or tablet. The liquid formulation must be accurately measured using a calibrated device to ensure the proper volume is taken, as the standard concentration is 0.4% (2 mg per 5 mL).


Dosing and Scheduling

The total daily dosage is established through a strict titration process and must be highly individualized. Treatment typically begins with a low initial dose, such as 1 mg on the first day. The dose is then gradually increased by 2 mg increments, usually at intervals of three to five days, until the optimal therapeutic regimen is reached.


Administration Conditions and Adjustments

For stable intake, the total daily amount is generally administered in divided doses throughout the day, commonly in three parts. Patients requiring higher total daily amounts may have the dose split into four separate administrations. The medicine may be taken with meals to minimize the potential for gastric irritation, or alternatively before meals if the primary concern is managing excessive dry mouth.

Official procedural guidance specifies that older adults should always start on a low dose that is increased very gradually. Additionally, abrupt withdrawal of the medicine is officially cautioned against. If a dose is missed, instructions advise skipping the missed dose entirely if it is almost time for the next scheduled dose, strictly prohibiting the practice of doubling the subsequent dose to compensate.

Recent Clinical Evidence

Research evidence / Overview of studies for Artane 0.4%

Evidence for Use in Core Indications

Research exploring the use of Trihexyphenidyl for Parkinsonism is supported by short-term clinical trials and a significant history of clinical experience, leading to an evidence level classified as moderate. These studies primarily examined changes in motor features, such as the severity of tremor and muscle rigidity, often comparing the study drug against placebo. For Drug-Induced Movement Disorders (EPS), the evidence base is far more restricted, consisting mainly of case reports and observational studies referenced by regulators, and is classified as low. Scientific literature notes that evidence is lacking or inconsistent for preventing certain forms of EPS. Similarly, research focused on specific, severe involuntary movements like dystonia has relied on small-scale pilot studies and cross-over trials in select populations, such as children. This specific evidence base is also rated as limited due to small sample sizes.

Evidence Gaps and Limitations

The current evidence landscape highlights several key uncertainties. While some historical summaries describe patient characteristics over multi-year courses, the majority of contemporary, high-quality research is focused on short-term or intermediate follow-up periods. Long-term effects are not fully established, and there is limited information on the durability of any observed response over many years. Furthermore, research focused on special populations, such as children with secondary dystonia, is scarce, and the certainty remains low because sample sizes were modest. Comparative evidence is lacking to definitively contrast this medicine against newer therapies for some indications, and it is not yet clear which specific patient subgroups are most likely to observe a change in symptoms.

Key Studies & References

  1. Trihexyphenidyl Hydrochloride Solution Label (DailyMed/NIH)

Frequently Asked Questions (FAQ)

Common questions about Artane 0.4% (FAQ)


Q: Is Artane 0.4% considered a type of Parkinson's medication?

Yes, the official indications and usage documents state that Artane (trihexyphenidyl) is used for the symptomatic treatment of Parkinson's disease. It is also approved for treating drug-induced extrapyramidal symptoms, which are movement issues caused by certain other medications.


Q: Is there a list of drug types to avoid while on Artane 0.4%?

Official prescribing information advises caution when taking other medicines that have anticholinergic effects (such as certain antidepressants or phenothiazines) or those that act as CNS depressants (such as alcohol or sedatives). Combining these drug types with Artane can lead to additive side effects like increased drowsiness or other anticholinergic effects.


Q: How long after starting Artane 0.4% might it take to notice an effect?

According to scientific literature on its properties, Artane is considered a relatively fast-acting medication. The reported onset of action is generally described as being within 1 hour after taking an oral dose, with the peak effect typically observed around 2 to 3 hours after administration.


Q: Can Artane 0.4% be used during pregnancy or while breastfeeding?

Regulatory documents classify Artane as Pregnancy Category C. This classification indicates that animal studies have shown a risk to the fetus, but the potential benefits of the drug may be considered to outweigh the potential risks in certain clinical situations. Additionally, its use is generally not recommended while breastfeeding as it may inhibit lactation.


Q: Is there a generic version of Artane 0.4% available?

Yes, the active ingredient in Artane is trihexyphenidyl hydrochloride. This active ingredient is available as a generic medication, offered in both tablet and oral solution forms.


Q: Is Artane 0.4% similar to Cogentin (benztropine)?

Artane (trihexyphenidyl) and Cogentin (benztropine) belong to the same anticholinergic drug class. Both work by blocking muscarinic receptors and are used to manage movement disorders. Because of their similar function, information exists for healthcare providers regarding the relative potencies of the two drugs.


Q: Is it common for people to feel restless or anxious when taking Artane 0.4%?

Adverse reaction reports include feelings of nervousness, anxiety, restlessness, and agitation as possible effects. These reactions are typically reported in the nervous system and psychiatric categories, particularly with higher dosages.


Q: Can Artane 0.4% affect my sleep?

Yes, official reports list side effects such as drowsiness and insomnia (difficulty falling or staying asleep). It may also cause disturbances to normal sleep patterns in some individuals.


Q: Does Artane 0.4% affect appetite or weight?

Adverse event information indicates that loss of appetite (anorexia) has been reported as a side effect. In some rare instances, particularly documented in the pediatric population, weight loss has also been reported.


Q: Are there specific instructions for taking Artane 0.4% if I wear contact lenses?

Because Artane has anticholinergic effects, official warnings note that it can cause the eyes to become dry. If you wear contact lenses, this dryness may lead to increased lens awareness or blurred vision, potentially requiring the use of lubricating drops.


Q: Is Artane 0.4% safe to use before driving or operating machinery?

Regulatory advice cautions that Artane may cause side effects such as drowsiness, dizziness, and impaired judgment. Regulatory documents officially caution against performing hazardous activities requiring complete mental alertness, such as driving or operating machinery, until individuals are certain how the medicine affects them.


Q: What should I know about Artane 0.4% and hot weather?

Official warnings note that Artane may cause impaired sweating (anhidrosis), which is the body's inability to cool itself. Caution is advised during physical exercise, in the presence of fever, or when exposed to high environmental temperatures, as this lack of sweating can lead to a severe, potentially fatal, increase in body temperature (hyperthermia).


Q: Does Artane 0.4% help with all types of tremors?

Artane is officially indicated for the tremor associated with Parkinson's disease and drug-induced movement disorders. Regulatory documents and official indications do not list the treatment of Essential Tremor as a formal use condition.


Q: Can Artane 0.4% be used to treat dystonia?

While the official indications are for Parkinson's disease, it is sometimes used by healthcare providers to manage symptoms of dystonia. Scientific literature confirms there is ongoing research and clinical experience examining its use for this condition.


Q: Does Artane 0.4% have any long-term side effects that are common?

Adverse event reports indicate that the development of angle-closure glaucoma has been associated with the long-term use of Artane (trihexyphenidyl). This is a severe condition and is the reason the medicine is strictly contraindicated in patients who have narrow-angle glaucoma.


Q: Are there any known issues with taking Artane 0.4% and allergy medicines (antihistamines)?

Yes, regulatory warnings advise caution when combining Artane with certain allergy medicines (antihistamines). This is because many of these medicines also have anticholinergic activity, and the combination may lead to additive side effects such as increased drowsiness, dry mouth, or blurred vision.


Q: What is the difference between Artane tablets and the Artane liquid form?

Artane is available in both tablet and oral solution (liquid) forms. The liquid formulation provides a specific concentration that allows for precise volume measurements that may be required when making small dose adjustments. The liquid and regular-release tablets have similar characteristics regarding when they start working.


Q: Does Artane 0.4% have any effect on blood pressure?

Adverse event reports mention effects on heart rate, including both tachycardia (fast heart rate) and bradycardia (slow heart rate). Official prescribing information advises caution for patients who have high blood pressure (hypertension) or pre-existing heart conditions.


Q: Is Artane 0.4% a slow-acting or fast-acting medication?

Artane is considered a fast-acting medication. Studies indicate that the reported onset of action occurs within 1 hour of taking an oral dose.


Q: How is Artane 0.4% cleared from the body?

The medicine is primarily metabolized (broken down) in the liver by enzymes. Scientific literature reports that the drug's elimination half-life is generally described as approximately 3 to 4 hours.


Q: What is the typical timeframe for a follow-up appointment after starting Artane 0.4%?

Official guidance emphasizes the need for close monitoring for specific side effects, such as changes in intraocular pressure (eyes) and signs of impaired sweating. Because the medicine requires a gradual adjustment phase to find the optimal regimen, official guidance emphasizes the need for close clinical monitoring during the initial treatment phase.

How should Artane 0.4% be stored and disposed of?

How to Store and Dispose of Artane 0.4%?

The storage and disposal of Artane (trihexyphenidyl HCl) oral solution must strictly follow regulatory guidelines to maintain product integrity and ensure safety.

Required Storage Conditions

Item Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C, with excursions between 15 C and 30 C).
Handling Protect from freezing.
Child Safety Store out of the reach of children.

Disposal Instructions

Unused or expired Artane 0.4% must be disposed of in accordance with applicable federal, state, and local laws and regulations for pharmaceutical waste. Disposal instructions mandate adherence to official guidelines for discarding the medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Artane 0.4% found in:

A-Z Index: